Home New Customer? Create Account
Member Login:

BR322 Origin Plasmids

OG12 - pSF-CMV-BR322 Ori

PRICE

Starting at: $307.00

Please Choose:

Shipping Option



Enter Quantity:


This plasmid is compatible with all of the other DNA sequences available on this site, which are all sold in the same backbone. This flexibility allows you to create any vector you require, with a variety of functions, simply by compiling the relevant sections from our product range.

Product Code:  OG12

Size (bp):  5130

Bacterial Antibiotic Selection:  Kanamycin

Origin and Compatibility:  BR322 origin low/intermediate-copy origin (15-20 copies per cell), derived from plasmid pBR322.

Copy Number: 15-20 copies per cell

Promoter: Cytomegalovirus (CMV) immediate early promoter

Purpose: Provides a low to intermediate copy plasmid, which allows greater stability of difficult to clone, unstable, or toxic, DNA sequences.

Transcription Termination: This plasmid contains three alternative transcription terminators for mammalian, bacterial and bacteriophage (T7) expression. This means that only the promoter needs to be changed to alter the expression system you are using. We sell multiple promoters that can be used in each of these systems. The presence of each terminator does not reduce expression in the alternative systems.

Inserting a Gene: Each restriction site in this vector has a purpose and allows the insertion of specific pre-designed DNA sequences. To insert a gene, we recommend using any sites between (and including) the HindIII and XbaI sites. By doing this you will be able to insert most of our other products upstream, or downstream, of your gene. Click here to read more about the purpose of each restriction site.

Intellectual Property Status: According to our IP-friendly policy, this plasmid is sold free of reach-through rights on any derivatives you may create.

Quality Validation: This plasmid has been demonstrated to express reporter genes to high levels under the CMV promoter. The start codon of these reporters was positioned within the NcoI site and the stop codon was positioned within the XbaI site. Expression was validated in the A549 lung carcinoma cell line. The origin has been validated to produce the correct number of copies in E.coli. 

Quality Sequencing Analysis: This vector has been fully sequenced using primers F1-F10. The sequences and details of these primers are available through our website.

Genetic Modifications to standard parts:

  • CMV promoter – an NcoI site has been ablated in the CMV promoter. This change does not reduce expression.
  • KanR cassette – This KanR resistance region is not a wild type sequence, it has been modified to remove all restriction sites that conflict with the SnapFast system and to retain a high level of antibiotic resistance. It has been validated in E.coli.

 Restriction site notes:

  • Bgl2, KpnI, SwaI and PmeI each cut the plasmid at two sites positioned to flank the promoter, start codon, origin, and KanR, respectively.
  • BsgI and BseRI recognise non-palindromic DNA sequences and cleave upstream of their recognition sites, within the stop codon that is found inside the XbaI restriction site.
  • The BR322 origin contains PciI, BspHI and BsgI sites. These sites conflict with certain product ranges in the SnapFastTMsystem, such as the downstream IRES insertions and the C-terminal fusion range. We are currently ablating these restrictions sites. When this is completed the new vector will replace this one.